Skip to main content
Verified Statutory Healthcare Resource — Indian Pharmacopoeia (IP) / CDSCO / PMBJP Jan Aushadhi Standards
Antibiotics & Infections 5 min read • Last Updated: September 2026

Monocef 1g (Ceftriaxone Injection): Hospital Indications, Typhoid & IV Administration

Clinical monograph of Monocef 1g (Ceftriaxone IV/IM): bacterial meningitis, severe hospital sepsis, complicated typhoid, and skin allergy test...

Statutory Medical Disclaimer & Emergency Safety Notice The pharmacological and therapeutic data presented in this educational guide is synthesized exclusively for public health literacy, academic reference, and educational purposes in conformity with the Indian Pharmacopoeia (IP 2022) and guidelines established by the Central Drugs Standard Control Organisation (CDSCO). This content does not constitute medical diagnosis, formal physician opinion, or individualized therapeutic instruction. Under the Drugs and Cosmetics Act, 1940 and the National Medical Commission (Professional Conduct) Regulations, Schedule H, H1, and X pharmaceutical formulations must be prescribed and monitored by a registered medical practitioner (RMP). Patients must not initiate, alter, or terminate any therapeutic drug regimen without formal clinical evaluation by their treating physician or a licensed healthcare professional. For acute medical emergencies, dial 112 / 108 (India) immediately.
🩺 Quick Clinical Answer

Monocef contains Ceftriaxone 1g, a broad-spectrum third-generation cephalosporin administered via IV infusion or deep IM injection. It is indicated for severe infections including bacterial meningitis, hospital-acquired pneumonia, multi-drug resistant typhoid, and surgical prophylaxis.

1. Critical Hospital Infection Control

Ceftriaxone crosses the blood-brain barrier effectively, making it a frontline treatment for bacterial meningitis and neurological infections. It has high protein binding and an 8-hour elimination half-life, allowing once or twice-daily dosing.

2. Mandatory Skin Hypersensitivity Test

In Indian hospitals, a dilute intradermal test dose (0.1ml) is standard practice before starting the full IV infusion to rule out severe IgE-mediated anaphylactic shock.

3. Jan Aushadhi Generic Savings

Branded Monocef 1g vial costs ~₹70.00. The Jan Aushadhi generic Ceftriaxone 1g dry powder injection costs just ₹24.00 (66% savings).

PMBJP Jan Aushadhi Price Transparency

Top 8 Essential Indian Medicines: Branded MRP vs. Jan Aushadhi Generic Comparison

Compare average Indian retail MRP of top branded formulations against government-certified PMBJP Jan Aushadhi bioequivalent generic prices and active salts. Verified against official PMBJP formularies, NPPA price caps, and CDSCO regulatory registries.

Brand Name Leading Manufacturer Active Salt Formulation (IP) Branded MRP Jan Aushadhi Price Savings %
Augmentin 625 Duo GlaxoSmithKline Pharmaceuticals Amoxicillin Trihydrate 500mg + Potassium Clavulanate 125mg IP ₹220.00 ₹58.00 74%
Dolo 650 Micro Labs Ltd Paracetamol (Acetaminophen) 650mg IP ₹34.00 ₹5.50 84%
Pantocid 40 Sun Pharmaceutical Industries Pantoprazole Sodium 40mg IP (Gastro-resistant) ₹155.00 ₹8.00 95%
Azithral 500 Alembic Pharmaceuticals Azithromycin Dihydrate 500mg IP ₹132.00 ₹24.00 82%
Glycomet 500 USV Private Limited Metformin Hydrochloride 500mg IP ₹24.00 ₹4.50 81%
Shelcal 500 Torrent Pharmaceuticals Elemental Calcium 500mg + Cholecalciferol (Vit D3) 250 IU IP ₹134.00 ₹16.00 88%
Telma 40 Glenmark Pharmaceuticals Telmisartan 40mg IP ₹92.00 ₹7.50 92%
Montair-LC Cipla Ltd Montelukast Sodium 10mg + Levocetirizine Dihydrochloride 5mg IP ₹210.00 ₹18.00 91%
Combined 8-Drug Essential Therapy Basket Total: ₹1,001.00 ₹141.00 85.9% Net Savings
Additional high-volume Indian medicines bioequivalent generic savings: Atorva 10 (Atorvastatin 10mg: Branded ₹110.00 vs Jan Aushadhi ₹12.00, 89% savings), Allegra 120 (Fexofenadine 120mg: Branded ₹215.00 vs Jan Aushadhi ₹32.00, 85% savings). Official Portal: PMBJP National Formulary (janaushadhi.gov.in) →

Frequently Asked Questions (Clinical & Regulatory)

Q1: Can Ceftriaxone be mixed with Ringer's Lactate (calcium) IV fluids?

NO. Ceftriaxone forms insoluble precipitates with calcium-containing IV solutions (like Ringer's Lactate), which can cause fatal organ microemboli.

Q2: Can Monocef 1g be given at home?

Monocef should only be administered by trained healthcare nurses or doctors equipped with emergency anaphylaxis kits (adrenaline).

Q3: Why must patients finish the complete prescribed course of antibiotics?

Discontinuing antibiotics prematurely upon early symptomatic relief leaves partially suppressed bacterial colonies alive. These surviving pathogens rapidly develop genetic mutation mechanisms and plasmid-mediated resistance against active pharmaceutical salts, driving Antimicrobial Resistance (AMR).

Q4: What are CDSCO Schedule H1 regulations for Indian antibiotics?

Schedule H1 drugs—including third-generation cephalosporins, carbapenems, and fluoroquinolones—require registered medical practitioner prescriptions and must be recorded by pharmacies in dedicated physical registers noting doctor and patient details, held for 3 years to curb irrational antibiotic use.

Q5: Does Jan Aushadhi generic Amoxicillin + Clavulanate provide the same bacterial clearance as Augmentin 625?

Yes. Government-certified Jan Aushadhi Amoxicillin (500mg) + Potassium Clavulanate (125mg) IP meets identical pharmacopoeial standards for beta-lactamase enzyme inhibition, delivering equivalent infection resolution at ₹58.00 vs ₹220.00 branded MRP.

MediMatch AI Clinical Pharmacology Review Board
Clinically reviewed by Dr. Vikram Anand, MBBS, MD (Clinical Pharmacology), Dr. Aditi Sharma, MD Pharmacology & Dr. Rajesh Nair, PharmD, RPh

This clinical guide is authored and reviewed in accordance with the regulatory standards of the Indian Pharmacopoeia (IP), Central Drugs Standard Control Organization (CDSCO) drug schedules, and Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) bioequivalence guidelines. All therapeutic recommendations and drug interaction warnings are cross-referenced with official statutory publications.

Official Statutory References: Indian Pharmacopoeia Commission (ipc.gov.in) → PMBJP Jan Aushadhi Portal (janaushadhi.gov.in) → CDSCO Health & Family Welfare (cdsco.gov.in) →
Digital Personal Data Protection (DPDP) Act, 2023 Statutory Health Privacy Disclosure

Under India's Digital Personal Data Protection (DPDP) Act, 2023, MediMatch AI functions as a data fiduciary committed to zero retention of private health identifiers. Browsing educational guides, reviewing active salt monographs, and executing search queries occur without tracking or commercial profiling. All client interactions with prescription readers or lab decoders execute ephemerally in volatile memory with zero server-side storage of protected health information (PHI). For inquiries regarding data fiduciary obligations, contact our Data Protection Officer at privacy@medimatchai.in.